Mangiferin, a natural xanthone, accelerates gastrointestinal transit in mice involving cholinergic mechanism

World Journal of Gastroenterology

Volumn 18, Issue 25, 2012, Pages 3207-3214

  Morais, Talita Cavalcante ^a   Lopes, Synara Cavalcante ^a   Carvalho, Karine Maria Martins Bezerra ^a,b   Arruda, Bruno Rodrigues ^a   de Souza, Francisco Thiago Correia ^a   Trevisan, Maria Teresa Salles ^a   Rao, Vietla Satyanarayana ^a   Santos, Flávia Almeida ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Federal University of Ceará   (Brazil)

Author keywords

Cholinergic mechanism; Gastrointestinal transit; Glucosylxanthone; Mangiferin; Prokinetic action

Indexed keywords

CAPSAICIN; CLONIDINE; MANGIFERIN; ONDANSETRON; TEGASEROD; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC ACTIVITY; CONSTIPATION; CONTROLLED STUDY; DRUG ISOLATION; GASTROINTESTINAL TRANSIT; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; WATER CONTENT;

EID: 84863889190     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i25.3207     Document Type: Article

References (42)

1. DiJoseph JF, Taylor JA, Mir GN. Alpha-2 receptors in the gastrointestinal system: a new therapeutic approach. Life Sci 1984; 35: 1031-1042
2. Firth M, Prather CM. Gastrointestinal motility problems in the elderly patient. Gastroenterology 2002; 122: 1688-1700
3. Camilleri M, Tack JF. Current medical treatments of dyspepsia and irritable bowel syndrome. Gastroenterol Clin North Am 2010; 39: 481-493
4. Chang HY, Kelly EC, Lembo AJ. Current gut-directed therapies for irritable bowel syndrome. Curr Treat Options Gastroenterol 2006; 9: 314-323
5. Walters JB, Montagnini M. Current concepts in the management of opioid-induced constipation. J Opioid Manag 2010; 6: 435-444
6. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25: 599-608
7. Kinoshita Y, Hashimoto T, Kawamura A, Yuki M, Amano K, Sato H, Adachi K, Sato S, Oshima N, Takashima T, Kitajima N, Abe K, Suetsugu H. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005; 21 Suppl 2: 37-41
8. Saad R, Chey WD. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. Expert Rev Gastroenterol Hepatol 2008; 2: 497-508
9. Peeters TL, Vantrappen G, Janssens J. Fasting plasma motilin levels are related to the interdigestive motility complex. Gastroenterology 1980; 79: 716-719
10. Venkatasubramani N, Rudolph CD, Sood MR. Erythromycin lacks colon prokinetic effect in children with functional gastrointestinal disorders: a retrospective study. BMC Gastroenterol 2008; 8: 38
11. Wallace JL, Ferraz JG. New pharmacologic therapies in gastrointestinal disease. Gastroenterol Clin North Am 2010; 39: 709-720
12. Loyd RA, McClellan DA. Update on the evaluation and management of functional dyspepsia. Am Fam Physician 2011; 83: 547-552
13. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313
14. Chey WD, Howden CW, Tack J, Ligozio G, Earnest DL. Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. Dig Dis Sci 2010; 55: 684-697
15. Attaluri A, Donahoe R, Valestin J, Brown K, Rao SS. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther 2011; 33: 822-828
16. Kakino M, Izuta H, Ito T, Tsuruma K, Araki Y, Shimazawa M, Oyama M, Iinuma M, Hara H. Agarwood induced laxative effects via acetylcholine receptors on loperamideinduced constipation in mice. Biosci Biotechnol Biochem 2010; 74: 1550-1555
17. El-Seedi HR, El-Barbary MA, El-Ghorab DM, Bohlin L, Borg-Karlson AK, Göransson U, Verpoorte R. Recent insights into the biosynthesis and biological activities of natural xanthones. Curr Med Chem 2010; 17: 854-901
18. Amazzal L, Lapôtre A, Quignon F, Bagrel D. Mangiferin protects against 1-methyl-4-phenylpyridinium toxicity mediated by oxidative stress in N2A cells. Neurosci Lett 2007; 418: 159-164
19. Márquez L, García-Bueno B, Madrigal JL, Leza JC. Mangiferin decreases inflammation and oxidative damage in rat brain after stress. Eur J Nutr 2011; Epub ahead of print
20. Barreto JC, Trevisan MT, Hull WE, Erben G, de Brito ES, Pfundstein B, Würtele G, Spiegelhalder B, Owen RW. Characterization and quantitation of polyphenolic compounds in bark, kernel, leaves, and peel of mango (Mangifera indica L.). J Agric Food Chem 2008; 56: 5599-5610
21. Leiro J, Arranz JA, Yáñez M, Ubeira FM, Sanmartín ML, Orallo F. Expression profiles of genes involved in the mouse nuclear factor-kappa B signal transduction pathway are modulated by mangiferin. Int Immunopharmacol 2004; 4: 763-778
22. Lemus-Molina Y, Sánchez-Gómez MV, Delgado-Hernández R, Matute C. Mangifera indica L. extract attenuates glutamate-induced neurotoxicity on rat cortical neurons. Neurotoxicology 2009; 30: 1053-1058
23. Pardo Andreu GL, Maurmann N, Reolon GK, de Farias CB, Schwartsmann G, Delgado R, Roesler R. Mangiferin, a naturally occurring glucoxilxanthone improves long-term object recognition memory in rats. Eur J Pharmacol 2010; 635: 124-128
24. Canuto KM, de Souza Neto MA, Garruti DS, Colho de Lima MA. Evaluation of the use of ethylene inhibitors on production of volatile compounds and mangiferin in mango fruit. Quim Nova 2010; 33: 1535-1540
25. Nadkarni KM. Indian Materia Medica. Vol. 1. Mumbai: Popular Prakashan, 1993: 805-806
26. Carvalho AC, Guedes MM, de Souza AL, Trevisan MT, Lima AF, Santos FA, Rao VS. Gastroprotective effect of mangiferin, a xanthonoid from Mangifera indica, against gastric injury induced by ethanol and indomethacin in rodents. Planta Med 2007; 73: 1372-1376
27. Capasso F, De Ruggiero G, Di Rosa M, Sorrentino L. [Pharmacological research on a deethylate metabolite of 4-amino5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide (metoclopramide)]. Boll Chim Farm 1976; 115: 649-657
28. Izzo AA, Mascolo N, Borrelli F, Capasso F. Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 65-70
29. Suchitra AD, Dkhar SA, Shewade DG, Shashindran CH. Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in mice. World J Gastroenterol 2003; 9: 779-783
30. Zarate N, Spencer NJ. Chronic constipation: lessons from animal studies. Best Pract Res Clin Gastroenterol 2011; 25: 59-71
31. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750-759
32. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004; 18: CD001960
33. Iwata H, Tsuchiya S, Nakamura T, Yano S. Morphine leads to contraction of the ileal circular muscle via inhibition of the nitrergic pathway in mice. Eur J Pharmacol 2007; 574: 66-70
34. Ruwart MJ, Klepper MS, Rush BD. Clonidine delays small intestinal transit in the rat. J Pharmacol Exp Ther 1980; 212: 487-490
35. Umezawa T, Guo S, Jiao Y, Hisamitsu T. Effect of clonidine on colonic motility in rats. Auton Neurosci 2003; 107: 32-36
36. Furness JB. The enteric nervous system: normal functions and enteric neuropathies. Neurogastroenterol Motil 2008; 20 Suppl 1: 32-38
37. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414
38. Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, Omagari K, Takeshima F, Kohno S. Recent insights into digestive motility in functional dyspepsia. J Gastroenterol 2006; 41: 1025-1040
39. Fayyaz M, Lackner JM. Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther Clin Risk Manag 2008; 4: 41-48
40. Yoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 1993; 43: 1078-1083
41. Hirota CL, McKay DM. Cholinergic regulation of epithelial ion transport in the mammalian intestine. Br J Pharmacol 2006; 149: 463-479
42. Stephens DP, Thomas JH, Collins SJ, Goldrick PB, Fowler S. A clinical audit of the efficacy of tegaserod as a prokinetic agent in the intensive care unit. Crit Care Resusc 2008; 10: 71